phone icon  Int'l : +1 (503) 505-6949
Shopping Cart is Empty..
$ 0

World Lung Cancer Therapeutics Market

- Opportunities and Forecasts, 2014 -2020
 Report Code: LI 15351
 Pages: NA
 Format: PDF Exel CD_rom
pub_n Upcoming Date: Nov 2015
tab_nTables: NA

Lung cancer is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs’ ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss. Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.

Global lung cancer therapeutics market shows promising CAGR due to increasing population of lung cancer and it is expected that trend would continue with the same momentum. Advanced stages of lung cancer still show high unmet need for diagnosis and treatment. The potential drivers for lung cancer therapeutic market include tobacco smoking (including passive smoke), aged population and lifestyle factors. Additionally, innovative and targeted drug delivery to lung is found to be a major driver for the growth of this market. However, high unmet need for diagnosis, availability of large number of generic forms of major drugs and limited treatment options are the critical restrains to the global lung cancer therapeutics market. Chemotherapy and radiation therapy poses bigger challenge of adverse effect. Hence, big players in this market have to focus on innovative therapies and safer therapeutics. 

Global Lung Cancer Therapeutics Market by TherapeuticsThe global lung cancer therapeutics market is segmented by therapy into five broad categories, namely Chemotherapy, Targeted therapy and Pipeline drugs, Surgery and Radiotherapy. NSCLC contributes for high prevalence than SCLC. Avastin by Roche was the blockbuster drug for the past few years that accounted for major percentage of the total sale. Other top brands of therapeutics include Gemzar, Taxotere and Tarceva and used for NSCLC. For SCLC treatment, ifosfamide or etoposide is combined with platinum analog and forms standard chemotherapeutic regimen. Many a times, Radiotherapy in combination with chemotherapy, is used as better option before surgery to increase the effectiveness of the treatment. Key Challenge in successful pipeline therapy includes its integration with existing therapy or its superiority over existing therapy.

Global Lung Cancer Therapeutics Market by GeographyGeographically, global lung cancer therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe are the leading global lung cancer therapeutic markets due to high incidences and large pool of aging population. Additionally, lifestyle standard with high smoking habits leads to a large pool of lung carcinoma population. Asia-Pacific is the emerging market, where India has shown high incidence in past few years, whereas, LAMEA contributes to smaller volume as compared to North America and Europe.

Competitive LandscapeThe leading companies in global lung cancer therapeutics market include Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Pfizer, and Agennix AG. Currently, Roche, Agennix AG and Pfizer are ruling the market for global lung cancer therapeutics and expected to capture half of the market share during the forecast period. Decline in sales value of AstraZeneca was attributed to large number of generic drugs entering the market. Eli Lilly has achieved a top position next to AstraZeneca and Sanofi-Aventis due to exceptional sales performance of its key product Alimta.  

High Level AnalysisThe study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global lung cancer therapeutics market, their operating strategies, new launches, pipeline therapies and clinical trials. Porter’s five forces analysis has been used to determine the attractiveness of global lung cancer therapeutics market. Chemotherapy and radiation therapy shows large number of side effects and many a times need to be followed by surgery. Hence, constant demand for safe and efficacious therapeutics and improved technology is responsible to increase the bargaining power of suppliers. Large number of generic drugs is entering the market and therefore, the threat of substitute products tends to be high. To fulfill the demand for safe and effective drug therapy, many companies are putting their effort to pipeline research. Thus, it led to commercialization of large number of products and due to which rivalry is intense among participants.


  • This report offers the following benefits in particular:
  • Comprehensive coverage of global lung cancer therapeutics market along with disease overview, market trends, drivers and restraints
  • Through attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities, would be beneficial to understand the future market trends  
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global lung cancer therapeutics market

KEY DELIVERABLESThe global lung cancer therapeutics market is segmented into two major categories such as, therapeutics and geography. MARKET BY THERAPY

  • Chemotherapy
    • Taxotere
    • Hycamtin
    • Navelbine
    • Gemzar
    • Alimta
  • Targeted therapy
    • Tarceva
    • Iressa
    • Avastin
  • Pipeline drugs
    • Talactoferrin 
    • Dacomitinib
    • Afatinib
    • Erbitux
    • ARQ 197
    • Ramucirumab
  • Surgery
    • Pneumectomy (Removal of whole lung)
    • Bilobectomy (Removal both lobes)
    • Lobectomy (removal of one lobe)
  • Radiotherapy


  • North America
  • Europe
  • Asia-Pacific
Let us know more about your research need and we will customize an offer exclusively for you!

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Delivery Formats
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
Need to add more ?

Get This Report
buy now
First time buyer ?
Check offers and discount
on this report
Need More Information
phone_n +1 (503) 505-6949

Help AMR
Send Enquiry
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
  • ...
    The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart.
    Aug 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Nonalcoholic Steatohepatitis (NASH) also known as silent disease is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication.
    Aug 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market.
    Feb 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Surgical equipment are medical devices/tools that serve the specific purpose during surgery. These tools enable the physical modification of biological tissue to provide access to underlying body components. The global surgical equipment market is expected to grow at significant CAGR of 11.1% during the forecast period. Inception of modern electronic technologies such as minimally invasive surgery equipment, and robotic & power assisted systems are primarily driving the surgical equipment market.
    Jul 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Vaccine is a preparation of weak or killed pathogen to stimulate the immunity process of the body. The vaccine market is a segment under the pediatric drugs market, which accounts to 80% of the pharmaceutical drugs market. The demand for pediatric vaccines is the major driving force of the market. This is due to high birth rates in the developing countries that accounted to 97% in 2012. The major restraint is the side effects produced by the vaccines.
    Nov 2015 | View Details >>
  • ...
    Cardiovascular diseases (CVD) are one of the foremost public health challenge across the globe. According to World Organization (WHO) estimate, about 17.5 million people died from cardiovascular diseases in 2012, accounting for 31% of all global deaths. Around one third of CVD deaths take place in the low and middle income countries. By the year 2030, more than 23 million people are likely to die annually from cardiovascular diseases.
    Nov 2015 | View Details >>
  • ...
    Cancer has been globally affecting 10million people and it is expected to increase by 2.4% by 2020, reaching to 14 million. Cervical Cancer is a form of cancer that forms in the cervix region of the female reproductive system. The cancer is usually a slow developing type of cancer which may or may not show symptoms of the diseases.
    Nov 2015 | View Details >>
  • ...
    Particle size analysis is an analytical technique through which samples containing particulate material is distributed, measured and reported. This particulate material present could be in solid or liquid form. It is essential to analyze the particle’s size as it affects the material’s functioning. Increasing adoption of particle size analyzers in nanotechnology is contributing tothe growth of this market
    Nov 2015 | View Details >>